CEL-SCI CORPORATION APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CEL-SCI CORPORATION (CVM) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.78 million for the 3-month period ending 2020-03-31, per its 10-Q/A filed 2020-12-30.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2020-12-30
- CEL-SCI CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2020-03-31 was $1.78M, a 235.51% increase year-over-year.
- CEL-SCI CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2019-12-31 was $1.80M, a 213.81% increase year-over-year.
- CEL-SCI CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2019-06-30 was $1.52M, a 226.93% increase year-over-year.
- CEL-SCI CORPORATION apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2019-03-31 was $530.83K, a 89.71% increase year-over-year.
- CEL-SCI CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2018 was $2.74M, a 85.20% increase from fiscal 2017.
- CEL-SCI CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2017 was $1.48M, a 26.40% decline from fiscal 2016.
- CEL-SCI CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2016 was $2.01M, a 60.58% decline from fiscal 2015.
- CEL-SCI CORPORATION apic, share-based payment arrangement, increase for cost recognition for fiscal 2015 was $5.11M, a 28.98% increase from fiscal 2014.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2020-03-31 | $1.78M 10-Q/A · filed 2020-12-30 | $3.58M derived: sum of 2 quarters · filed 2020-12-30 | ||
| 2019-12-31 | $1.80M 10-Q/A · filed 2020-12-30 | |||
| 2019-06-30 | $1.52M 10-Q · filed 2019-08-14 | $2.05M derived: sum of 2 quarters · filed 2020-12-30 | $2.63M derived: sum of 3 quarters · filed 2020-12-30 | |
| 2019-03-31 | $530.83K 10-Q/A · filed 2020-12-30 | $1.10M derived: sum of 2 quarters · filed 2020-12-30 | ||
| 2018-12-31 | $573.66K 10-Q/A · filed 2020-12-30 | |||
| 2018-09-30 | $2.74M 10-K · filed 2018-12-19 | |||
| 2018-06-30 | $465.49K 10-Q · filed 2019-08-14 | $745.30K derived: sum of 2 quarters · filed 2019-08-14 | $2.19M derived: sum of 3 quarters · filed 2019-08-14 | |
| 2018-03-31 | $279.82K 10-Q · filed 2019-08-14 | $1.73M derived: sum of 2 quarters · filed 2019-08-14 | ||
| 2017-12-31 | $1.45M 10-Q · filed 2019-08-14 | |||
| 2017-09-30 | $1.48M 10-K · filed 2018-12-19 | |||
| 2016-09-30 | $2.01M 10-K · filed 2017-12-29 | |||
| 2015-09-30 | $5.11M 10-K/A · filed 2017-12-11 | |||
| 2014-09-30 | $3.96M 10-K/A · filed 2017-12-11 | |||
| 2013-09-30 | $2.64M 10-K · filed 2015-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |